Inactivation of TFEB and NF-κB by marchantin M alleviates the chemotherapy-driven pro-tumorigenic senescent secretion.
Acta Pharm Sin B
; 9(5): 923-936, 2019 Sep.
Article
em En
| MEDLINE
| ID: mdl-31649843
ALT, glutamic-pyruvic transaminase; AST, transaminase; BUN, blood urea nitrogen; CDDP, cisplatin; CI, combinatory index; CM, conditioned media; CREA, creatinine; CT-like, both chymotrypsin-like; DMSO, dimethyl sulfoxide; Doc, docetaxel; Doxo, doxorubicin; Drug resistance; EdU, 5-ethynyl-2'-deoxyuridine; LPS, lipopolysaccharide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Mar-M, Marchantin M; Marchantin M; NF-κB; NF-κB, nuclear factor-κB; PGPH, peptidylglutamyl hydrolyzing; PI, propidium iodide; ROS, reactive oxygen species; SA-ß-gal, senescence-associated ß-galactosidase; SASP; SASP, senescence-associated secretory phenotype; Sv, starvation; TCGA, the Cancer Genome Atlas; TFEB; TFEB, transcription factor EB; Tg, thapsigargin
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Acta Pharm Sin B
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
China
País de publicação:
Holanda